Olema Oncology Reports Q2 2024 Results And Corporate Update
06 Aug 2024 //
GLOBENEWSWIRE
Olema Presents Promising Palazestrant + Ribociclib Data At ESMO Breast Congress
15 May 2024 //
GLOBENEWSWIRE
Olema Palazestrant+Ribociclib Breast Cancer Data At ESMO
08 May 2024 //
GLOBENEWSWIRE
Olema Oncology Q1 2024 Financials, Corporate Update
08 May 2024 //
GLOBENEWSWIRE
Olema Oncology Announces Publication of Data Highlighting Palazestrant™s Ability
06 Mar 2024 //
GLOBENEWSWIRE
Olema Announces Palazestrant Demonstrates Combinability with CDK4/6 Inhibitors
05 Dec 2023 //
GLOBENEWSWIRE
Olema to Present Palazestrant Data in Combination with CDK4/6 Inhibitors
28 Nov 2023 //
GLOBENEWSWIRE
Olema Oncology Announces Positive Phase 2 Study Results for Palazestrant
22 Oct 2023 //
GLOBENEWSWIRE